The contract development and manufacturing company has finalized its agreement with Elanco to own and operate its manufacturing site in Speke, UK.
TriRx Pharmaceutical Services—a contract development and manufacturing company—has finalized and closed its agreement to acquire ownership and operations of the Elanco Health Incorporated manufacturing site in Speke, United Kingdom. TriRx and Elanco settled on a 2-facility sale and long-term agreement that covers the site in Speke as well as a facility in Shawnee, Kansas.
“The Speke facility deal constitutes the second part of our acquisition and supply agreement with Elanco, following our closing on the Shawnee, Kansas facility in August 2021. We look forward to continuing our successful strategic partnership with this global leader,” said Timothy C, Tyson, chairman and CEO of TriRx, in an organizational release. “This important two-facility acquisition represents a significant step in our strategy to be a leading global CDMO in both animal health and human health."
“We welcome the skilled workforce at Speke to TriRx,and look forward to growing this team as we invest in the site, fulfilling the long-term supply agreement with Elanco Animal Health and bringing in new business as part of our strategic plan," he continued.
According to the release, the Speke facility can manufacture both human and animal health products. With the acquisition, TriRx will receive the physical assets on the site as well as a transfer of 350 employees. As part of the agreement, TriRx will still provide Elanco with reliable delivery of Elanco products.
“Since the sale of the Shawnee facility to TriRx in August last year, our partnership has been very successful, and we are delighted to complete this next step with the Speke facility sale and continue our long-term strategic supply agreement with a major supplier that shares our vision,” stated Dave Urbanek, executive vice president of manufacturing and quality.
TriRx Completes Acquisition of Elanco Manufacturing Facility in Speke, United Kingdom. News release. TriRx Pharmaceutical Services. February 8, 2022. Accessed February 10, 2022.